NervGen is a biotech company dedicated to discovering and developing treatments for patients suffering from medical conditions related to nerve damage.
NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration, remyelination and plasticity. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various indications.
NervGen’s lead product is NVG-291 which we are planning to develop for spinal cord injury, multiple sclerosis and Alzheimer’s disease.
NervGen’s core technology targets protein tyrosine phosphatase sigma (PTPσ), a neural receptor that impedes nerve regeneration, remyelination and plasticity. Inhibition of the PTPσ receptor has been shown to promote regeneration of damaged nerves and improvement of nerve function in animal models for various indications.
NervGen’s lead product is NVG-291 which we are planning to develop for spinal cord injury, multiple sclerosis and Alzheimer’s disease.
Ticker:
TSX-V: NGEN; OTCQX: NGENF
Exchange:
TSX-V; OTCQX
Company Type:
Publicly Traded Company
Company Website:
Company HQ State:
British Columbia
Company HQ Country:
Canada
Year Founded:
Not Provided
Main Therapeutic Focus:
Regenerative Medicine
Lead Product in Development:
NVG-291
Development Phase of Primary Product:
Pre-Clinical
Number Of Unlicensed Products (For Which You Are Seeking Partners):
Not Provided
Speaker
